NATURE REVIEWS DRUG DISCOVERY

Scope & Guideline

Exploring the latest in drug development science.

Introduction

Immerse yourself in the scholarly insights of NATURE REVIEWS DRUG DISCOVERY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1474-1776
PublisherNATURE PORTFOLIO
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationNAT REV DRUG DISCOV / Nat. Rev. Drug Discov.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

Nature Reviews Drug Discovery is dedicated to providing comprehensive reviews and insights into the evolving landscape of drug discovery and development. The journal's primary focus lies in facilitating a deeper understanding of the scientific and technological advancements that shape the pharmaceutical industry.
  1. Drug Discovery Mechanisms:
    The journal extensively covers the mechanisms underlying drug discovery, including target identification, lead optimization, and preclinical development, highlighting innovative methodologies and technologies.
  2. Therapeutic Areas:
    Nature Reviews Drug Discovery addresses a wide range of therapeutic areas, including oncology, neurology, infectious diseases, and autoimmune disorders, providing insights into current trends and future directions in these fields.
  3. Emerging Technologies:
    The journal emphasizes the role of emerging technologies in drug discovery, such as artificial intelligence, gene editing, and novel drug delivery systems, showcasing how these innovations can enhance drug development processes.
  4. Clinical Development and Regulatory Landscapes:
    The journal discusses the challenges and strategies associated with clinical trials and regulatory approvals, offering critical analyses of recent FDA approvals and the implications for drug development.
  5. Personalized Medicine and Precision Therapeutics:
    Nature Reviews Drug Discovery explores the advancements in personalized medicine, focusing on how genetic and molecular profiling can inform drug development and improve patient outcomes.
Recent publications in Nature Reviews Drug Discovery reveal several emerging themes and trends that reflect the current priorities and interests of the drug discovery community.
  1. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is rapidly increasing, with a focus on improving target identification, predictive modeling, and optimizing drug design.
  2. Gene Therapy and Genetic Medicines:
    There is a growing emphasis on gene therapy approaches, including CRISPR and RNA-based therapies, which are seen as revolutionary methods for treating genetic disorders and complex diseases.
  3. Immunotherapy Innovations:
    The field of immunotherapy is witnessing significant advancements, particularly in CAR-T cell therapies and bispecific antibodies, which are becoming key areas of research in oncology.
  4. Microbiome Research in Drug Development:
    The role of the microbiome in drug metabolism and therapeutic efficacy is gaining attention, leading to new strategies for drug development that consider microbiome interactions.
  5. Regenerative Medicine and Tissue Engineering:
    Emerging research on regenerative medicine and tissue engineering is highlighting novel therapeutic strategies for treating degenerative diseases and injuries, marking a shift towards more holistic treatment approaches.

Declining or Waning

As the field of drug discovery evolves, certain themes and areas of focus may decline in prominence. Recent analyses indicate a waning interest in specific topics that were previously prominent in the literature.
  1. Traditional Small Molecule Drug Discovery:
    While still relevant, there has been a noticeable shift towards biologics, gene therapies, and advanced therapeutic modalities, leading to a decline in the emphasis on traditional small molecule approaches.
  2. Conventional Monoclonal Antibodies:
    The exploration of conventional monoclonal antibodies is decreasing, as the field moves towards bispecific antibodies, antibody-drug conjugates, and other innovative formats that offer improved efficacy and specificity.
  3. Single-Target Approaches:
    The focus on single-target drug discovery is declining in favor of multi-target strategies that consider the complexity of diseases, particularly in oncology and chronic conditions.
  4. Standard Clinical Trial Designs:
    There is a diminishing focus on traditional clinical trial designs, with increasing interest in adaptive trial designs and real-world evidence to better evaluate drug efficacy and safety.
  5. Cytokine-Based Therapies:
    Interest in cytokine-based therapies appears to be waning, as researchers explore more targeted and less toxic immunotherapeutic options.

Similar Journals

Recent Patents on Anti-Cancer Drug Discovery

Pioneering Research for a Cancer-Free Future
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8928Frequency: 4 issues/year

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Journal of Pharmacy & Pharmacognosy Research

Elevating Standards in Pharmaceutical Science
Publisher: JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRESISSN: 0719-4250Frequency: 6 issues/year

Journal of Pharmacy & Pharmacognosy Research, published by JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRES, is a prominent open-access journal established in 2013, headquartered in Antofagasta, Chile. With a focus on the fields of Complementary and Alternative Medicine, Drug Discovery, Pharmaceutical Science, Pharmacology, and Pharmacy, this journal is recognized for its commitment to advancing research and disseminating knowledge within these important areas. With a current impact factor that reflects its academic rigor and relevance, the journal has achieved substantial recognition, evident by its Q2 and Q3 quartile rankings in multiple categories, indicating its growing influence on the scientific community. The Scopus rankings further highlight its standing in pharmacy and pharmacological disciplines, providing a valuable platform for researchers, professionals, and students to share their findings and insights. With its open access model, the journal ensures that high-quality research is available to a global audience, paving the way for collaborative advancements in pharmaceutical sciences.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Elevating clinical practice with innovative pharmacotherapy findings.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Pharmaceutical Sciences

Pioneering research at the intersection of science and health.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

TRENDS IN PHARMACOLOGICAL SCIENCES

Bridging Knowledge and Practice in Pharmacological Sciences
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Fostering collaboration in the realm of cardiovascular pharmacology.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

Drug Target Insights

Unveiling Innovations in Therapeutic Targeting.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

SCIENTIA PHARMACEUTICA

Exploring new horizons in pharmaceutical research.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

CLINICAL THERAPEUTICS

Transforming therapeutic strategies through rigorous research.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

Expert Review of Precision Medicine and Drug Development

Elevating the standards of drug development and genetic research.
Publisher: TAYLOR & FRANCIS LTDISSN: 2380-8993Frequency: 6 issues/year

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.